Supplementary Table S4 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Supplementary table S4 - Most Common (≥10% of Patients) Adverse Events
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Lung Cancer Treatments and Mutations
Cancer Genomics and Diagnostics
Publication details
- Publication date
- 16 March 2026
- Language
- EN